BioCorRx (BICX) Saham Harga

BioCorRx Harga

OTC·DITUTUP
0,25
​
Pasar ditutup

Selama 15 tahun terakhir pendapatan BioCorRx tumbuh 12,3% per tahun, mencapai 797.244,00 USD. Bagi BioCorRx, margin bersih sebesar -431,5% naik dibanding -10.789,4% beberapa tahun lalu.

Harga saham BioCorRx

Akses data ini lewat Eulerpool API

Model bisnis dan analisis saham BioCorRx

BioCorRx Inc adalah perusahaan Amerika Serikat yang didirikan pada tahun 2008 dan berpusat di Anaheim, California. BioCorRx mengkhususkan diri dalam pengembangan dan pemasaran metode pengobatan inovatif untuk ketergantungan alkohol dan narkoba. Sejarah BioCorRx dimulai dengan peluncuran produk andalannya, Program Pemulihan BioCorRx, yang didasarkan pada teknologi medis baru bernama Implan Naltrexone/Buprenorphine. Berbeda dengan metode tradisional untuk mengobati kecanduan alkohol dan narkoba yang biasanya mengandalkan obat-obatan dan dukungan psikoterapi, Program Pemulihan BioCorRx adalah sistem pengobatan jangka panjang yang dapat ditanamkan dan secara terus-menerus melepaskan bahan aktif Naltrexone atau Buprenorphine ke dalam tubuh pasien. Ide di balik hal ini adalah bahwa bahan aktif tersebut mencegah gejala putus zat sehingga mengurangi risiko kambuh. Dalam beberapa tahun terakhir, BioCorRx telah memperluas portofolio produknya dan mengembangkan aktivitas bisnisnya ke segmen-segmen baru untuk lebih mendorong pertumbuhan perusahaan. Hal ini mencakup bidang layanan telemedicine, yang memungkinkan BioCorRx menawarkan teknologi pengobatan dan layanan medisnya melalui komunikasi daring. Layanan telemedicine seperti konsultasi pasien virtual atau program terapi kelompok daring sangat diminati selama masa pandemi COVID-19. Fokus lain dari BioCorRx adalah manajemen tenaga medis. Studi menunjukkan bahwa perawatan dan konseling pasien yang baik sangat memengaruhi keberhasilan pengobatan. BioCorRx kini juga telah mengembangkan platform sendiri yang memudahkan dan meningkatkan manajemen, pelatihan, serta pemantauan staf medis. BioCorRx juga memanfaatkan konsep sistem waralaba untuk memasarkan produk dan layanannya. Sistem waralaba ini menawarkan kesempatan kepada profesional medis dan organisasi yang bergerak di bidang pengobatan kecanduan untuk membuka klinik BioCorRx mereka sendiri dan menawarkan produk serta layanan perusahaan di pasar lokal masing-masing. Setiap klinik diberi nasihat dan didukung oleh BioCorRx serta harus mematuhi standar dan kriteria kualitas tertentu. Ke depan, BioCorRx berencana untuk mendiversifikasi penawaran produknya lebih lanjut dan mengembangkan teknologi baru untuk meningkatkan opsi pengobatan bagi penderita ketergantungan alkohol dan narkoba. Contoh teknologi semacam itu adalah obat berbasis Ibogaine. BioCorRx telah memulai penelitian awal di arah ini dan secara aktif mengerjakan studi pra-klinis. Secara keseluruhan, BioCorRx adalah perusahaan yang terutama berfokus pada teknologi inovatif untuk pengobatan kecanduan. Perusahaan telah mengalami pertumbuhan substansial dalam beberapa tahun terakhir dengan memperluas jangkauan produk dan basis pelanggan, serta berfokus pada area telemedicine, manajemen personel, dan sistem waralaba. Dengan teknologi visionernya dan penekanan kuat pada kualitas serta kepuasan pasien, BioCorRx diharapkan akan terus memainkan peran penting dalam pengobatan kecanduan di tahun-tahun mendatang.

Pertanyaan yang sering diajukan tentang saham BioCorRx

The business model of BioCorRx Inc revolves around providing innovative solutions for the treatment of substance abuse and addiction. The company specializes in developing and commercializing behavioral healthcare products and services. BioCorRx Inc offers the BioCorRx Recovery Program, which combines medication-assisted treatment with counseling and peer support. This comprehensive approach aims to help individuals overcome substance abuse by addressing the underlying factors contributing to addiction and promoting long-term recovery. By integrating medical and behavioral components, BioCorRx Inc strives to provide effective solutions for patients seeking to break free from addiction.

BioCorRx Inc is primarily active in the healthcare and pharmaceutical industries.

The main competitors of BioCorRx Inc in the market include pharmaceutical companies, such as Pfizer Inc, Johnson & Johnson, and Novartis AG. Other competitors in the addiction treatment industry include Alkermes plc and Indivior Inc. These companies operate in the same market, offering various products and services for addiction treatment. BioCorRx Inc, a leader in medication-assisted treatment solutions, competes with these companies through its innovative treatment program, BioCorRx Recovery.

BioCorRx Inc is a pharmaceutical company specializing in innovative addiction treatment solutions. Established in 2008, BioCorRx is dedicated to developing effective medications and programs to support those struggling with alcohol and opioid dependencies. The company focuses on combining its proprietary medication, known as the BioCorRx® Recovery Program, with cognitive-behavioral therapy to enhance patient outcomes and reduce relapse rates. With a mission to improve the lives of individuals battling addiction, BioCorRx Inc strives to provide comprehensive and personalized treatment options. Through its commitment and innovative approach, BioCorRx Inc has positioned itself as a leading player in the addiction treatment industry.

BioCorRx Inc, a leading pharmaceutical company, has accomplished several significant milestones in recent years. One of their key achievements includes the development and commercialization of their flagship product, the BioCorRx Recovery Program, which offers a unique, non-addictive approach to treating substance abuse. The company has also made remarkable strides in expanding their distribution networks, forging partnerships with healthcare professionals, and achieving regulatory approvals for their innovative products. Moreover, BioCorRx Inc has consistently demonstrated a commitment to research and development, continually exploring new avenues for improving addiction treatment. These accomplishments highlight BioCorRx Inc's dedication to revolutionizing the field of substance abuse recovery.

BioCorRx Inc is primarily present in the United States. Recognized as a leader in substance use disorder treatment, BioCorRx operates its headquarters in Anaheim, California. With a focus on developing innovative solutions for addiction recovery, the company's presence spans the entire US territory. BioCorRx Inc is dedicated to helping individuals overcome addiction and promoting healthier lives.

BioCorRx Inc represents a strong set of values and a dedicated corporate philosophy. The company is committed to providing innovative solutions in the field of substance use disorder treatment. BioCorRx focuses on developing safe and effective approaches to help individuals overcome addiction and reclaim their lives. With a patient-centric approach, the company aims to provide comprehensive programs that combine medication-assisted treatment with behavioral support. BioCorRx exemplifies integrity, compassion, and a commitment to improving the well-being of individuals struggling with addiction. Through their cutting-edge solutions, BioCorRx Inc strives to make a positive impact in the field of addiction treatment and contribute to the overall betterment of society.

Dengan kurs saat ini, saham BioCorRx diperdagangkan pada 0,22 EUR (0,25 USD).

BioCorRx Inc is a leading biotechnology company that develops innovative health solutions for the treatment of addiction disorders. The company specializes in the development and sale of medications for the treatment of drug and alcohol addiction. The company has two different divisions: BioCorRx Pharmaceuticals and BioCorRx Health. BioCorRx Pharmaceuticals focuses on the research, development, and marketing of naltrexone micro-implants for use in alcohol and opioid addiction. These micro-implants are small, biocompatible pellets that are implanted under the skin to allow for continuous release of naltrexone, reducing withdrawal symptoms. BioCorRx Pharmaceuticals also holds a license for the development of buprenorphine implants for the treatment of opioid addiction. The second division, BioCorRx Health, offers a unique integrative health solution for the treatment of addiction disorders. This program includes a variety of services, including program guidance, phone support, online courses, nutritional counseling, exercise therapy, and acupuncture. The program is based on the BioCorRx Recovery Formula, a patented approach that is truly personalized to the patient and their needs. In addition, BioCorRx Inc offers a range of additional products that help reduce addictive behavior and enhance the success of the program. These include capsules for support during withdrawal, special supplements for patients with N-acetylcysteine deficiency, and enhanced vitamin and mineral supplements. BioCorRx Inc has established a strong presence in the US market and is expanding its global presence. The company has formed strategic partnerships with distribution partners to market its products and services worldwide. BioCorRx has also built excellent relationships with addiction researchers, medical professionals, and leading addiction treatment centers. The business model of BioCorRx Inc is based on two pillars: the marketing of patented medications for the treatment of addiction disorders and the sale of integrative health solutions. The company aims to offer a complete, integrated program for the treatment of addiction disorders, which includes both pharmacological treatments and supportive services. Due to the high demand for effective addiction treatments and the high demand for innovative solutions, BioCorRx Inc's business is promising. The company is well positioned to continue growing and dominate the addiction treatment market. The translation is as follows: BioCorRx Inc is a leading biotechnology company that develops innovative health solutions for the treatment of addiction disorders. The company specializes in developing and selling medications to treat drug and alcohol addiction. The company has two divisions: BioCorRx Pharmaceuticals and BioCorRx Health. BioCorRx Pharmaceuticals focuses on researching, developing, and marketing naltrexone micro-implants for alcohol and opioid addiction. These micro-implants are small, biocompatible pellets implanted under the skin to release naltrexone continuously and reduce withdrawal symptoms. BioCorRx Pharmaceuticals also holds a license to develop buprenorphine implants for opioid addiction. BioCorRx Health offers a unique integrative health solution for addiction treatment, including program guidance, phone support, online courses, nutrition counseling, exercise therapy, and acupuncture. The program is based on the BioCorRx Recovery Formula, a patented approach tailored to each patient's needs. Additionally, BioCorRx Inc provides products to reduce addictive behavior and enhance program success. These include withdrawal support capsules, special supplements for N-acetylcysteine deficiency, and improved vitamin and mineral supplements. With a strong presence in the US market and plans for global expansion, BioCorRx Inc has formed strategic partnerships to market its products and services worldwide. The company has also established relationships with addiction researchers, medical professionals, and leading addiction treatment centers. BioCorRx Inc's business model focuses on marketing patented addiction medications and selling integrative health solutions. The company strives to offer a comprehensive program that combines pharmaceutical treatments with supportive services. Given the high demand for effective addiction treatments and innovative solutions, BioCorRx Inc is well positioned for growth and market dominance in addiction treatment.

Pendapatan diperkirakan dari BioCorRx adalah 971.850,00 USD. Angka ini didasarkan pada data keuangan terkini dan mencerminkan kinerja bisnis perusahaan.

Laba diperkirakan dari BioCorRx adalah -2,20 Juta. USD. Laba bersih mencerminkan profitabilitas perusahaan setelah mengurangi semua biaya.

Rasio harga-terhadap-pendapatan (PER) BioCorRx saat ini adalah -2,79. PER membandingkan harga saham saat ini dengan laba per saham dan membantu investor menilai valuasi saham BioCorRx.

Rasio harga-terhadap-penjualan (PSR) BioCorRx saat ini adalah 6,30. PSR membandingkan kapitalisasi pasar dengan pendapatan tahunan dan berfungsi sebagai metrik valuasi untuk saham BioCorRx.

Skor Kualitas AlleAktien untuk BioCorRx adalah 3/10.

ISIN dari BioCorRx adalah US09073C2052. ISIN (International Securities Identification Number) adalah identifikasi unik global untuk sekuritas.

WKN dari BioCorRx adalah A1XERB. WKN (Wertpapierkennnummer) adalah kode identifikasi sekuritas Jerman enam digit.

Ticker dari BioCorRx adalah BICX. Simbol ticker digunakan untuk memperdagangkan saham BioCorRx di bursa saham.

Nilai WajarTerminal
0,21 USD
Penilaian Berlebihan/KurangTerminal
Dinilai secara wajar
Sektor
Industri
Penyedia Layanan Kesehatan & Jasa
Jumlah Saham
Karyawan
Pendapatan per Karyawan
159.448,80 USD
Pertumbuhan Pendapatan Ø5 Tahun
Pertumbuhan EBIT Ø5 Tahun
Pertumbuhan Laba Bersih Ø5 Tahun
Situs Web biocorrx.com
Mata Uang
USD
Penawaran Umum Perdana
31 Agu 2010
ISIN
US09073C2052
CUSIP
09073C205
SEDOL
BGLSV90
Kapitalisasi Pasar
Kisaran 52 Minggu
Rasio PEG
—
P/E 2026
-2,79
P/E 2027
-3,19
P/S
P/S
6,30
EV/EBIT
—
Rasio P/B
8,54
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
30,84 %
Terakhir diperbarui 14 Okt 2026, 07.21

BioCorRx Ticker

OTC · BICXOTC · BICX

BioCorRx FIGI

BICX:US · BBG000Q34T88BICX:PQ · BBG000Q34Z48BICX:UV · BBG000Q351D2

Semua metrik fundamental dan analisis mendalam BioCorRx

Analisis saham kami untuk saham BioCorRx mencakup kalkulasi keuangan penting seperti pendapatan, keuntungan, P/E ratio (P/E), P/S ratio (P/S), EBIT, serta informasi tentang dividen. Selain itu, kami juga mengamati aspek-aspek seperti saham, kapitalisasi pasar, utang, ekuitas, dan kewajiban dari BioCorRx. Jika Anda mencari informasi lebih rinci tentang topik-topik ini, kami menawarkan analisis terperinci di subhalaman kami.